p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?
Open accessAbstract
The discovery of the p53 tumor suppressor protein in 1979 shed new light on cancer cell biology and introduced a trend in cancer research focusing on p53-like proteins. This in turn led to the discovery of two homologous proteins of p53-p63 in 1998 and p73 in 1997. The p53 family members are mainly involved in apoptosis induction under cellular stress, but also in early embryonic developmental processes. The p63 and p73 proteins activate the transcription of a number of p53 target genes. The precise role of p63 in cancer cells is not fully revealed yet, unlike that of p53 and p73. The p53 tumor suppressor protein is found inactive in approximately 50% of human cancers. However, p73 is not as often inactivated in tumors. Of importance, transcriptionally active forms of p73 induce apoptosis in cancer cells independent of p53 status. Moreover, the regulatory mechanisms governing p73 stability in cells are well described. These features promoted the research concerning p73-targeted anti-cancer treatment. The p73 protein is subject to sophisticated activatory and inhibitory regulatory mechanisms. The up-to-date anti-cancer compounds targeting p73 protein in vitro inhibit its negative regulators, which leads to the activation of p73 pro-apoptotic function in cancer cells. In the current review we present the recent scientific findings on p73 regulation in cells and the newest anti-cancer strategies concerning its tumor suppressor function.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
p73α has functions similar to p53 but is regulated differently by Mdm2.
“The p53 family member p73α has functions similar to p53 (17, 18, 42, 43), but is regulated differently by Mdm2.”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [42]
Cites
Still being checked.
Cited by
Sorted by citations
Steelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C., Long, J. M., Laidler, P. M., Mijatović, S., Maksimović‐Ivanić, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 689 · see citing works
Metabolic Regulation by p53 Family Members
Berkers, C. R., Maddocks, O. D. K., Cheung, E. C., Mor, I., & Vousden, K. H. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.06.019 · Cited by 443 · see citing works
The rebel angel: mutant p53 as the driving oncogene in breast cancer
Walerych, D., Napoli, M., Collavin, L., & Sal, G. D. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs232 · Cited by 287 · see citing works
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
Blandino, G., & Agostino, S. D. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0705-7 · Cited by 198 · see citing works
DNA binding partners of YAP/TAZ
Kim, M., Jang, J., & Bae, S. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.3.015 · Cited by 180 · see citing works
TGF-β1/p53 signaling in renal fibrogenesis
Higgins, S. P., Tang, Y., Higgins, C. E., Mian, B. M., Zhang, W., Czekay, R., Samarakoon, R., Conti, D. J., & Higgins, P. J. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.11.005 · Cited by 150 · see citing works
Rufini, A., Agostini, M., Grespi, F., Tomasini, R., Sayan, B. S., Niklison-Chirou, M. V., Conforti, F., Velletri, T., Mastino, A., Mak, T. W., et al. (2011) · Genes & Cancer · doi:10.1177/1947601911408890 · Cited by 138 · see citing works
Role of p63 in Development, Tumorigenesis and Cancer Progression
Bergholz, J. S., & Xiao, Z. J. (2012) · Cancer Microenvironment · doi:10.1007/s12307-012-0116-9 · Cited by 111 · see citing works
Pharmacological reactivation of p53 as a strategy to treat cancer
Zawacka‐Pankau, J., & Selivanova, G. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12336 · Cited by 82 · see citing works
Self-citationKPT-330 has antitumour activity against non-small cell lung cancer
Sun, H., Hattori, N., Chien, W., Sun, Q., Sudo, M., E-Ling, G. L., Ding, L., Lim, S. L., Shacham, S., Kauffman, M. G., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.260 · Cited by 74 · see citing works
Regulation of the p53 Family Proteins by the Ubiquitin Proteasomal Pathway
Bang, S., Kaur, S., & Kurokawa, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010261 · Cited by 69 · see citing works
Lü, J., Yang, L., Zhao, H., Liu, B., Li, Y., Wu, H., Li, Q., Zeng, B., Wang, Y., Ji, W., et al. (2011) · Human Mutation · doi:10.1002/humu.21574 · Cited by 62 · see citing works
ING1 and ING2: multifaceted tumor suppressor genes
Guérillon, C., Larrieu, D., & Pedeux, R. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1270-z · Cited by 62 · see citing works
A functional copy number variation in the WWOX gene is associated with lung cancer risk in Chinese
Yang, L., Liu, B., Huang, B., Deng, J., Li, H., Yu, B., Qiu, F., Cheng, M., Wang, H., Yang, R., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt019 · Cited by 61 · see citing works
Knoll, S., Fürst, K., Thomas, S., Baselga, S. V., Stoll, A., Schaefer, S., & Pützer, B. M. (2011) · Cell Cycle · doi:10.4161/cc.10.20.17856 · Cited by 50 · see citing works
Gene set enrichment analysis of alpha-glucosidase inhibitors from Ficus benghalensis
Khanal, P., & Patil, B. M. (2019) · Asian Pacific Journal of Tropical Biomedicine · doi:10.4103/2221-1691.260399 · Cited by 47 · see citing works
Peng, D., Hu, T., Soutto, M., Belkhiri, A., Zaika, A. I., & El-Rifai, W. M. (2013) · Gut · doi:10.1136/gutjnl-2013-304612 · Cited by 46 · see citing works
Taylor, J. R., Lehmann, B. D., Chappell, W. H., Abrams, S. L., Steelman, L. S., & McCubrey, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.315 · Cited by 46 · see citing works
Das, R., Bhattacharya, K., Sarkar, S., Samanta, S. K., Pal, B. C., & Mandal, C. (2013) · APOPTOSIS · doi:10.1007/s10495-013-0907-6 · Cited by 45 · see citing works
RetractedTransgenic and Knockout Mice Models to Reveal the Functions of Tumor Suppressor Genes
Taneja, P., Zhu, S., Maglic, D., Fry, E. A., Kendig, R. D., & Inoue, K. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7516 · Cited by 43 · see citing works
Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42 · see citing works
Sharif, T., Stambouli, M., Burrus, B., Emhemmed, F., Dandache, I., Auger, C., Étienne-Selloum, N., Schini‐Kerth, V. B., & Fuhrmann, G. (2013) · Journal of Functional Foods · doi:10.1016/j.jff.2013.04.007 · Cited by 42 · see citing works
Diverse roles of the scaffolding protein RanBPM
Suresh, B., Ramakrishna, S., & Baek, K. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.030 · Cited by 42 · see citing works
Halaby, M., Hakem, R., & Hakem, A. (2013) · Cell Cycle · doi:10.4161/cc.25785 · Cited by 39 · see citing works
JNK–NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress
Kostecka, A., Sznarkowska, A., Meller, K., Acedo, P., Shi, Y., Sakil, H. A. M., Kawiak, A., Lion, M., Królicka, A., Wilhelm, M., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.408 · Cited by 35 · see citing works
Self-citationp73 – NAV3 axis plays a critical role in suppression of colon cancer metastasis
Uboveja, A., Satija, Y. K., Siraj, F., Sharma, I., & Saluja, D. (2020) · Oncogenesis · doi:10.1038/s41389-020-0193-4 · Cited by 32 · see citing works
p73: From the p53 shadow to a major pharmacological target in anticancer therapy
Ramos, H., Raimundo, L., & Saraiva, L. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105245 · Cited by 31 · see citing works
Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system
Lemarié, F., Croft, D. R., Tate, R. J., Ryan, K. M., & Dufès, C. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.12.019 · Cited by 31 · see citing works
Tissue-specific expression of p73 C-terminal isoforms in mice
Grespi, F., Amelio, I., Tucci, P., Annicchiarico‐Petruzzelli, M., & Melino, G. (2012) · Cell Cycle · doi:10.4161/cc.22787 · Cited by 29 · see citing works
Discussion of some ‘knowns’ and some ‘unknowns’ about the tumour suppressor p53
Lieschke, E., Wang, Z., Kelly, G. L., & Strasser, A. (2018) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjy077 · Cited by 28 · see citing works
Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition
Shin, J., Ha, J., Lee, D.-H., Ryu, K., Bae, K., Park, B. C., Park, S. G., Yi, G., & Chi, S. (2015) · Cell Cycle · doi:10.1080/15384101.2014.998056 · Cited by 27 · see citing works
p53 family members — important messengers in cell death signaling in photodynamic therapy of cancer?
Acedo, P., & Zawacka‐Pankau, J. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c5pp00251f · Cited by 26 · see citing works
Self-citationRecent progress in genetics of aging, senescence and longevity: focusing on cancer-related genes
Berman, A. E., Leontieva, O. V., Natarajan, V., McCubrey, J. A., Demidenko, Z. N., & Nikiforov, M. A. (2012) · Oncotarget · doi:10.18632/oncotarget.889 · Cited by 23 · see citing works
Structural Basis for ASPP2 Recognition by the Tumor Suppressor p73
Canning, P., von Delft, F., & Bullock, A. N. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.08.005 · Cited by 22 · see citing works
Tackling hepatitis B virus-associated hepatocellular carcinoma—the future is now
Bharadwaj, M., Roy, G., Dutta, K., Misbah, M., Husain, M., & Hussain, S. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9412-6 · Cited by 21 · see citing works
Zhao, L., Fu, L., Xu, Z., Fan, R., Xu, R., Fu, R., Zou, S., Wang, C., Zhang, Y., Wang, J., et al. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10108 · Cited by 20 · see citing works
Huang, D., Qiu, F., Yang, L., Li, Y., Cheng, M., Wang, H., Ma, G., Wang, Y., Hu, M., Ji, W., et al. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21934 · Cited by 18 · see citing works
Targeting of p53 and its homolog p73 by protoporphyrin IX
Sznarkowska, A., Maleńczyk, K., Kadziński, L., Bielawski, K. P., Banecki, B., & Zawacka‐Pankau, J. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.12.004 · Cited by 17 · see citing works
Self-citationZawacka‐Pankau, J. (2020) · Cancers · doi:10.3390/cancers12092717 · Cited by 16 · see citing works
Self-citationPuppin, C., Passon, N., Frasca, F., Vigneri, R., Tomay, F., Tomaciello, S., & Damante, G. (2011) · Cellular Oncology · doi:10.1007/s13402-011-0009-9 · Cited by 16 · see citing works
Effects of carbon-ion beam or X-ray irradiation on anti-apoptosis ΔNp73 expression in HeLa cells
Di, C., Yang, L., Zhang, H., An, L., Zhang, X., Ma, X., Sun, C., Wang, X., Yang, R., Wu, Z.-H., et al. (2012) · Gene · doi:10.1016/j.gene.2012.11.040 · Cited by 14 · see citing works
Hanks, T. S., & Gauss, K. A. (2011) · APOPTOSIS · doi:10.1007/s10495-011-0672-3 · Cited by 14 · see citing works
Curcumin induces apoptosis in p53-null Hep3B cells through a TAp73/DNp73-dependent pathway
Wang, J., Xie, H., Gao, F., Zhao, T.-K., Yang, H., & Bai, K. (2015) · Tumor Biology · doi:10.1007/s13277-015-4029-3 · Cited by 14 · see citing works
The role of theTP73gene and its transcripts in neuro-oncology
Jančálek, R. (2014) · British Journal of Neurosurgery · doi:10.3109/02688697.2014.908162 · Cited by 14 · see citing works
Molecular and cellular pathways associated with chromosome 1p deletions during colon carcinogenesis
Payne, C. M., Crowley-Skillicorn, Bernstein, C., & Holubec (2011) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s17114 · Cited by 13 · see citing works
Pickart, L., Vasquez-Soltero, J. M., Pickart, F. D., & Majnarich, J. (2014) · Journal of Analytical Oncology · doi:10.6000/1927-7229.2014.03.02.2 · Cited by 12 · see citing works
P73 and age-related diseases: is there any link with Parkinson Disease?
Grespi, F., & Melino, G. (2012) · Aging · doi:10.18632/aging.100515 · Cited by 12 · see citing works
Structural dissection of the C-terminal sterile alpha motif (SAM) of human p73
Neira, J. L. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.07.005 · Cited by 10 · see citing works
Guo, H., Yang, S., Xu, L., Li, D., Tang, J., WANG, S., Wei, B., & Liu, Z. (2016) · Oncology Letters · doi:10.3892/ol.2016.4655 · Cited by 10 · see citing works
Hu, X., Wu, N., Xia, P., Yu, S., Sun, F., & Chen, J. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1823-0 · Cited by 8 · see citing works
Recent progress in targeting cancer
Demidenko, Z. N., & McCubrey, J. A. (2011) · Aging · doi:10.18632/aging.100421 · Cited by 8 · see citing works
Zeinab, R. A., Wu, H. H., Abuetabh, Y., Leng, S., Sergi, C. M., Eisenstat, D. D., & Leng, R. P. (2021) · Carcinogenesis · doi:10.1093/carcin/bgab009 · Cited by 6 · see citing works
Reduced WWOX protein expression in human astrocytoma
Winardi, W., Tsai, C., Chen, W., Tsai, H., Chung, C., Loh, J., Chai, C., & Kwan, A. (2013) · Neuropathology · doi:10.1111/neup.12040 · Cited by 5 · see citing works
Novel role of lncRNAs regulatory network in papillary thyroid cancer
Su, Y., Mei, L., Jiang, T., Jiang, T., Sun, T., Wu, Y., Wang, Z., & Ji, Y. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101674 · Cited by 4 · see citing works
Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells
Gillardin, P.-S., Descamps, G., Maïga, S., Tessoulin, B., Djamai, H., Lucani, B., Chiron, D., Moreau, P., Gouill, S. L., Amiot, M., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010040 · Cited by 4 · see citing works
Bareja, C., Dwivedi, K., Uboveja, A., Mathur, A., Kumar, N., V, & Saluja, D. (2024) · Scientific Reports · doi:10.1038/s41598-024-60715-1 · Cited by 3 · see citing works
TAp73 and ΔNp73 Relative Expression in Egyptian Patients with Lymphoid Neoplasms
Hamdy, M. S. E.-D., El-Saadany, Z. A., Makhlouf, M. M., Salama, A., Ibrahim, N. S., & Gad, A. (2016) · Tumori Journal · doi:10.5301/tj.5000506 · Cited by 3 · see citing works
Lin, C., Wang, C., Wang, S., Yang, C., Li, J., Chen, C.-S., Hung, S.-C., Chiu, K., Cheng, C., Ou, Y., et al. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.84364 · Cited by 2 · see citing works
Yuan, H., Wu, Y. F., Zhang, J., Shi, G., Liu, D., He, Y. M., Lu, Z., Wu, P., Jiang, K., & Miao, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s152140 · Cited by 2 · see citing works
The Role of Pirh2 E3 Ligases in Ubiquitination and p73 Regulation
Abou Zeinab, R. M. (2015) · ERA: Education and Research Archive (University of Alberta) · doi:10.7939/r3610vx4f · Cited by 1 · see citing works
von Roretz, C., & Gallouzi, I. (2013) · Wiley-VCH eBooks · doi:10.1002/3527600906.mcb.201200012
Modulation of the Mdm2 signaling axis sensitizes triple-negative breast cancer cells to carboplatin
Tonsing-Carter, E. Y. (2014) · ProQuest Demo Repository · doi:10.7912/c2/308
Dixon, A. S. (2014) · J. Willard Marriott Library · doi:10.26053/0h-6t82-gxg0
(2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416570-0.00043-3
Targeting Apoptotic Pathways in Melanoma
Hersey, P., & Zhang, X. D. (2011) · Springer eBooks · doi:10.1007/978-1-61779-407-0_9
Role of p53 and its isoforms in the expression of FGF-2 and tumoral neovascularization
Bernard, H. (2010) · Discovery Research Portal (University of Dundee)
- Authors
- Zawacka-Pankau, J., Kostecka, A., Sznarkowska, A., Hedström, E., & Kawiak, A.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2010-02-15
- Volume
- 9
- Issue
- 4
- Pages
- 720-728
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W2075794624
- Cited by
- 67
- References
- 0
- Citations by year
- 2024: 2 · 2023: 1 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 2 · 2015: 5 · 2014: 8 · 2013: 11 · 2012: 10
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Cell Cycle (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p73, p53 family, p63, tumor suppressor proteins, apoptosis, p53 target genes, embryonic development
- MeSH terms
- Tumor Protein p73, Antineoplastic Agents, DNA-Binding Proteins, Humans, Neoplasms, Nuclear Proteins, Photochemotherapy, Tumor Suppressor Protein p53, Apoptosis, Cyclin-Dependent Kinases, Tumor Suppressor Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
